Aardvark posts Phase 2 results for ARD-101 in Prader-Willi Syndrome
Results were listed for a completed Phase 2 study of ARD-101 in Prader-Willi Syndrome, with no serious adverse events reported in either dosing group.
Aardvark Therapeutics had one update this week, with results posted for its completed Phase 2 study of ARD-101.
- ARD-101, an oral drug, was tested in a Phase 2, single-arm study in patients with Prader-Willi Syndrome, sponsored by Aardvark Therapeutics with Children's Hospital Colorado and Stanford University as collaborators. The study enrolled 19 participants1 and reached completed status with a study completion date of September 24, 20241. Results posted showed zero of 13 participants in the fixed dose group and zero of 6 in the dose escalation group experienced serious adverse events1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.